Antisense oligonucleotides targeting hepatic angiotensinogen reduce atherosclerosis and liver steatosis in hypercholesterolemic mice
Global Translational Medicine · 24.02.2023 · 2 (1) · 288
DOI: 10.36922/gtm.288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Translational Medicine, online erschienen am 24.02.2023. Verfasst von Dien Ye und 10 weiteren Autor:innen. Beteiligte Einrichtung: Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Hepatocyte-derived angiotensinogen (AGT) is the precursor of angiotensin II (AngII). We determined the effects of hepatocyte-specific (N-acetylgalactosamine-conjugated) antisense oligonucleotides targeting AGT (GalNAc AGT ASO) on AngII-mediated blood pressure (BP) regulation and atherosclerosis and compared its effects with losartan, an AngII type 1 (AT1) receptor blocker, in hypercholesterolemic mice. Eight-week-old male low-density lipoprotein (LDL) receptor deficient mice were administered vehicle or GalNAc AGT ASO (1, 2.5, or 5 mg/kg) subcutaneously beginning 2 weeks before the initiation of Western diet feeding. All mice were fed Western diet for 12 weeks. Their systolic BP was monitored by the tail-cuff technique, and the atherosclerotic lesion area was measured by an en face method. Although the effects of all 3 doses of GalNAc AGT ASO on plasma AGT concentrations were similar, GalNAc AGT ASO reduced BP and atherosclerotic lesion size in a dose-dependent manner. Subsequently, we compared the effects of GalNAc AGT ASO (5 mg/kg) with losartan (15 mg/kg/day). Compared to losartan, GalNAc AGT ASO led to more profound increases in plasma renin and reduction in BP but had similar effects on atherosclerosis. Remarkably, GalNAc AGT ASO also reduced liver steatosis, which was not observed in losartan-treated mice. In conclusion, the BP increase and atherosclerosis development in hypercholesterolemic mice are dependent on AngII generated from hepatic AGT. Deleting hepatic AGT improves diet-induced liver steatosis, and this occurs in an AT1 receptor-independent manner.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA.
- Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands.
- Saha Aortic Center, University of Kentucky, Lexington, KY, USA.
- Department of Surgery, University of Kentucky, Lexington, KY, USA.
- Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, USA.
- Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY, USA.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Ye, D., Wu, C., Cai, L., Howatt, D. A., Liang, C. L., Katsumata, Y., Mullick, A. E., Temel, R. E., Danser, A. H. J., Daugherty, A., & Lu, H. S. (2023). Antisense oligonucleotides targeting hepatic angiotensinogen reduce atherosclerosis and liver steatosis in hypercholesterolemic mice. Global Translational Medicine, 2(1), 288. https://doi.org/10.36922/gtm.288
Vancouver
Ye D, Wu C, Cai L, Howatt DA, Liang CL, Katsumata Y, et al. Antisense oligonucleotides targeting hepatic angiotensinogen reduce atherosclerosis and liver steatosis in hypercholesterolemic mice. Global Translational Medicine. 2023;2(1):288. doi:10.36922/gtm.288
BibTeX
@article{Ye2023,
author = {Ye, Dien and Wu, Congqing and Cai, Lei and Howatt, Deborah A and Liang, Ching-Ling and Katsumata, Yuriko and Mullick, Adam E and Temel, Ryan E and Danser, A H Jan and Daugherty, Alan and Lu, Hong S},
title = {Antisense oligonucleotides targeting hepatic angiotensinogen reduce atherosclerosis and liver steatosis in hypercholesterolemic mice},
journal = {Global Translational Medicine},
year = {2023},
volume = {2},
number = {1},
pages = {288},
doi = {10.36922/gtm.288}
}
EUVIMED